MedTrace Logo

Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment

NCT00379405 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-12-04

No results posted yet for this study

Summary

Study the efficacy of Saquinavir/Ritonavir when given in single therapy as maintenance therapy, compared to standard HAART therapies.

Conditions

  • HIV Infections

Interventions

DRUG

Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours

Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours

Sponsors & Collaborators

  • Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

    collaborator OTHER

  • Germans Trias i Pujol Hospital

    lead OTHER

Principal Investigators

  • Clotet Bonaventura, MD,PhD · Hospital Universitari Germans Trias i Pujol. Badalona (Barcelona)

  • Negredo Eugenia, MD,PhD · Hospital Universitari Germans Trias i Pujol. Badalona. (Barcelona)

  • Echeverria Patricia, MD,PhD · Hospital Universitari Germans Trias i Pujol. Badalona. (Barcelona)

  • Molto Jose, MD,PhD · Hospital Universitari Germans Trias i Pujol. Badalona. (Barcelona)

  • Pere Domingo, MD, PhD · Hospital de Sant Pau

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-05-31
Completion
2008-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00379405 on ClinicalTrials.gov